Franklin-based Cumberland Pharmaceuticals today announced initial success showing their brand of injectable ibuprofen is safe for children. That’s key to the company’s plans for expansion. The drug maker is trying to find new markets for the three medications it currently sells.
Hospitals in the US already give Caldolor to adult patients, particularly before and after surgery. The new study tested it on tonsillectomy patients between the ages of 6 and 16. The hope is that the drug will be approved for all kinds of pediatric surgeries in the US.
At the same time, Cumberland Pharmaceuticals is working to sell all of its drugs in other countries. Caldolor is now approved for use in Canada, another can be sold in Australia and CEO AJ Kazimi says the company is moving forward in five other nations, including China.
“We’re already seeing contributions financially as we sign deals and over time we believe that this growing network of international partners will indeed provide a meaningful contribution to our business.”
Looking forward, a fourth medication is in the research stage, and Kazimi says the company is looking for a fifth.
Cumberland Pharmaceuticals generally doesn’t develop medications from the start; its main focus is on finding and buying the rights to drugs that are either almost ready for FDA approval or already through that process.
On Air - 90.3 WPLN-FM